Literature DB >> 11957023

Risk factors for breakthrough candidemia.

M Nucci1, A L Colombo.   

Abstract

In order to assess the risk factors for breakthrough candidemia (candidemia occurring in patients receiving at least 3 days of systemic fluconazole or amphotericin B), 270 cases of candidemia occurring in two tertiary hospitals were analyzed. Using multivariate analysis, profound neutropenia (<100/mm(3)) (odds ratio [OR], 9.14), use of corticosteroids (OR, 3.17), and heavy antibiotic exposure (previous use of 2 or more antibiotics for at least 14 days) (OR, 2.93) were identified as risk factors. Neither the susceptibility of the isolates nor the presence of a catheter was found to be a risk factor. These data suggest that gastrointestinal colonization plays a major role in the development of breakthrough candidemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11957023     DOI: 10.1007/s10096-002-0697-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

1.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

Review 2.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

3.  Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital.

Authors:  Tatiana Aporta Marins; Alexandre R Marra; Michael B Edmond; Marines Dalla Valle Martino; Paula Kiyomi Onaga Yokota; Ana Carolina Cintra Nunes Mafra; Marcelino Souza Durão Junior
Journal:  BMC Infect Dis       Date:  2018-04-18       Impact factor: 3.090

4.  In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.

Authors:  Cornelius J Clancy; Benjamin Staley; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

5.  Clinical and Microbiological Characteristics of Breakthrough Candidemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital.

Authors:  Muneyoshi Kimura; Hideki Araoka; Hisashi Yamamoto; Yuki Asano-Mori; Shigeki Nakamura; Satoshi Yamagoe; Hideaki Ohno; Yoshitsugu Miyazaki; Masahiro Abe; Mitsuhiro Yuasa; Daisuke Kaji; Kosei Kageyama; Aya Nishida; Kazuya Ishiwata; Shinsuke Takagi; Go Yamamoto; Naoyuki Uchida; Koji Izutsu; Atsushi Wake; Shuichi Taniguchi; Akiko Yoneyama
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

6.  Invasive Candida infections in patients of a medical intensive care unit: attempt of improving diagnosis by quantifying the colonization.

Authors:  Sebastian Kautzky; Thomas Staudinger; Elisabeth Presterl
Journal:  Wien Klin Wochenschr       Date:  2014-11-21       Impact factor: 1.704

7.  Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.

Authors:  William W Hope; George L Drusano; Caroline B Moore; Andrew Sharp; Arnold Louie; Thomas J Walsh; David W Denning; Peter A Warn
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

8.  High risk factors for pulmonary fungous infection in intensive care units of neurosurgery.

Authors:  Wenyu Zhu; Liping Tan; Xiangfeng Chen; Qiang Huang; Qing Lan
Journal:  Front Med China       Date:  2007-07

Review 9.  Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines.

Authors:  L Lee Dupuis; Paul C Nathan
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

10.  Candidaemia in patients with haematological disorders and stem cell transplant.

Authors:  Ka Al-Anazi; Am Al-Jasser
Journal:  Libyan J Med       Date:  2006-11-21       Impact factor: 1.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.